Dear Ms. Carey:

Please refer to your supplemental new drug application dated and received September 18, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lorbrena (lorlatinib) tablets.

This Prior Approval supplemental new drug application provides for revisions to the following subsections of the LORBRENA (lorlatinib) U.S. Prescribing Information (USPI):

- Section 2 DOSAGE AND ADMINISTRATION Subsection 2.6 Dosage Modification for Severe Renal Impairment
- Section 8 USE IN SPECIFIC POPULATIONS Subsection 8.7 Renal Impairment
- Section 12 CLINICAL PHARMACOLOGY Subsection 12.3 Pharmacokinetics of the Full Prescribing Information (FPI) with corresponding changes to the Patient Package Insert (PPI).

In addition, Highlights of Prescribing Information was updated to reflect revisions made to the FPI and minor formatting edits were made throughout the FPI.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling, with minor editorial revisions listed below and reflected in the enclosed labeling.

- Revised the date at the end of the Highlights of Prescribing Information to “2/2021” the most recent revision of the labeling.
- Patient Package Insert revised to include date of last revision as “Revised: February 2021”.

Reference ID: 4753569
WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the Food and Drug Administration (FDA) automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this new drug application (NDA), including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated September 18, 2020, containing the final report for the following postmarketing requirement listed in the November 2, 2018, approval letter:

3500-3 Complete a pharmacokinetic trial to determine an appropriate dose of lorlatinib to minimize toxicity in patients with severe renal impairment in accordance with the FDA Guidance for Industry entitled “Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling”.

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements listed in the November 2, 2018, approval letter that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

³ For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
⁴ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 4753569
If you have any questions, call Idara Udoh, Senior Regulatory Health Project Manager, at 301-796-3074.

Sincerely,

{See appended electronic signature page}

Abhilasha Nair, M.D.
Associate Director for Safety (acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:
- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ABHILASHA NAIR
02/26/2021 11:47:28 AM